New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
08:19 EDTARNAArena Pharma' and Eisai announce nomination of BELVIQ by Gallen Foundation
Eisai and Arena Pharmaceuticals (ARNA) announced that BELVIQ, or lorcaserin HCl, has been nominated by the Galien Foundation and Awards Committee for the 2014 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ was previously nominated for this award in 2013.
News For ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2015
08:06 EDTARNAEisai and Arena Pharmaceuticals complete trials of formulation of lorcaserin
Subscribe for More Information
April 7, 2015
09:23 EDTARNAOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTARNAArena Pharmaceuticals receives additional patent for Belviq from USPTO
Arena Pharmaceuticals and Eisai announced that the US Patent and Trademark Office granted Arena US Patent No. 8,999,970, which describes a method for selecting appropriate patients based on renal function for BELVIQ, a serotonin 2C receptor agonist approved for weight management. In addition to this method-of-treatment patent, composition of matter patents for BELVIQ are issued in major jurisdictions globally that, in most cases, are capable of continuing into 2023. Arena has filed applications for patent term extension on patents directed to composition of matter in the United States, which, if granted, would extend the composition of matter patent term for BELVIQ into 2026 or potentially 2027.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use